Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pharmacyte Biotech Inc (PMCB)

Pharmacyte Biotech Inc (PMCB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
PharmaCyte Biotech's Pancreatic Cancer Therapy Passes Critical FDA-Required Tests as Countdown to IND Submission Begins

PharmaCyte Biotech (OTCQB: PMCB) announced that its clinical trial product, which will be employed during the company's upcoming Phase 2b clinical trial to treat locally advanced, inoperable pancreatic...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech Successfully Completes All Release Tests on Clinical Trial Product

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech Addressing Unmet Need in Patients with LAPC as Pancreatic Cancer 5-Year Survival Rate Increases to 10%

This month the American Cancer Society announced that for the first time ever, the 5-year survival rate for pancreatic cancer has reached double digits. While this is certainly good news, the increase...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech Set to Reach Three Major Milestones in 2020

PharmaCyte Biotech's (OTCQB: PMCB) shareholders should expect 2020 to be the year that ushers in a host of much-anticipated milestones. This year the company's therapy for locally advanced, inoperable...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech Passing All Completed Tests on Clinical Trial Product

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech Provides Details on Quarterly Shareholder Update

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech Finalizes Pancreatic Cancer Treatment for U.S. FDA Approval to Begin Clinical Trial

PharmaCyte Biotech (OTCQB: PMCB) has a clinical trial product, a clinical trial protocol, including a clinical trial design, a Principal Investigator, and the company is ready to present its treatment...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech to Hold Quarterly Shareholder Update

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech "Release Testing" Successful on All Completed Tests of Clinical Trial Product

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech Successfully Completes Final Manufacturing Run of Clinical Trial Product

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech's "Release Testing" Last Critical Event Before Submission of Investigational New Drug Application

PharmaCyte Biotech (OTCQB: PMCB) has reduced a long list of FDA-required items to just one last important component--release testing--before it can submit an Investigational New Drug application (IND)...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech Closer to Submitting IND by Successfully Completing Encapsulation of Second Manufacturing Run of Clinical Trial Product

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology in Pancreatic Cancer Trial

PharmaCyte Biotech (OTCQB: PMCB) has a technology that could very well change the way a host of hard-to-treat diseases are treated for the foreseeable future. The company is closer than ever to its upcoming...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech Closer to Submitting IND with Successful Completion of Clinical Trial Product

PharmaCyte Biotech (OTCQB: PMCB) has now moved one step closer to submitting an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to request a clinical trial in...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech Successfully Completes Manufacturing of Clinical Trial Product

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech Q&A Discussion with Cellular Biologist David A. Judd

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech Releases Shareholder Update Call Playback Information

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech's Pancreatic Cancer Therapy Production in Final Days of Key Manufacturing Run

PharmaCyte Biotech (OTCQB: PMCB) and its partner, Austrianova, along with the company's cellular biologist, David Judd, are all more confident than ever that they have a product that can succeed in a U.S....

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech Provides Information on Upcoming Shareholder Update Call

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0580 (+1.93%)
PharmaCyte Biotech Releases Results of Shareholder Meeting and Provides Information on Upcoming Shareholder Update Call

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0580 (+1.93%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +1.49 , SEDG +3.72 , THC +1.79 , TER +1.55 , LITE +1.86
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar